Cello Health injects pharma duo to board of directors

Healthcare advisory group Cello Health on Thursday appointed independent non-executive directors Clifford Tompsett and Jo LeCouilliard to its board of directors.

The move follows Paul Hamilton and Will David standing down as non-executive directors with immediate effect after both having served as members of the AIM traded company’s board for more than a decade.

Mark Scott, chief executive of Cello, said: "I am delighted that the group has secured the services of two, highly experienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The board very much looks forward to working with Clifford and Jo as we shape the future growth path for the group."

Tompsett was most recently a senior partner at PriceWaterhouseCoopers, where he held responsibility over the firm's global cross border IPO practice and led its UK and European activities in the pharmaceutical sector, and will head the audit committee and serve as senior independent director.

Meanwhile, LeCouilliard, who is currently a non-executive director of Circassia Pharmaceuticals, has held a number of senior positions in Asia and the US at GlaxoSmithKline, as well as at BMI Healthcare.

Cello’s shares were up 0.77% at 131.50p at 1646 BST.